The new challenges in the prevention of cervical cancer

In the clinical trials, about 70% of girls and young sexually active women under 26 years with an average of two lifetime sexual partners were HPV DNA and serology negative (naives) for HPV 16 and 18 vaccine types. [...]among young women aged 14-25 years, the clearance rate of genital HPV infections is high, and disease occurs in a minority of women who can decrease their risk for cancer in settings where organized screening programs are available (REF) [1].